Menu
GWAS Study

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Clark SL, Souza RP, Adkins DE et al.

23241943 PubMed ID
GWAS Study Type
738 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CS
Clark SL
SR
Souza RP
AD
Adkins DE
AK
Aberg K
BJ
Bukszár J
MJ
McClay JL
SP
Sullivan PF
VD
van den Oord EJ
Chapter II

Abstract

Summary of the research findings

Objective: To examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia.

Up to 421 European ancestry Schizophrenia cases, up to 214 African American individuals, up to 103 individuals

Chapter III

Study Statistics

Key metrics and study information

738
Total Participants
GWAS
Study Type
No
Replicated
European, African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.